Schizophrenia Research
Volume 77, Issue 2 , Pages 167-177 , 15 September 2005

Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia

  • Xinhua S. Ren

      Affiliations

    • Health Services Department, Boston University School of Public Health, Boston, MA, USA
    • Center for Health Quality, Outcomes, and Economic Research, Veterans Affairs Medical Center, Bedford, MA, USA
    • Corresponding Author InformationCorresponding author. Center for Health Quality, Outcomes, and Economic Research, Veterans Affairs Medical Center, 200 Springs Road, Building 70, Bedford, MA 01730, USA. Tel.: +1 781 687 2957; fax: +1 781 687 3106.
    • ,
  • Lewis E. Kazis

      Affiliations

    • Health Services Department, Boston University School of Public Health, Boston, MA, USA
    • Center for Health Quality, Outcomes, and Economic Research, Veterans Affairs Medical Center, Bedford, MA, USA
    • ,
  • Austin F. Lee

      Affiliations

    • Health Services Department, Boston University School of Public Health, Boston, MA, USA
    • Center for Health Quality, Outcomes, and Economic Research, Veterans Affairs Medical Center, Bedford, MA, USA
    • Department of Mathematics and Statistics, Boston University, Boston, MA, USA
    • ,
  • Yu-Hui Huang

      Affiliations

    • Health Services Department, Boston University School of Public Health, Boston, MA, USA
    • Center for Health Quality, Outcomes, and Economic Research, Veterans Affairs Medical Center, Bedford, MA, USA
    • ,
  • Alaa Hamed

      Affiliations

    • Health Services Department, Boston University School of Public Health, Boston, MA, USA
    • ,
  • Francesca Cunningham

      Affiliations

    • Pharmacy Benefits Management Strategic Group, Department of Veterans Affairs, Hines, IL, USA
    • Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago, IL, USA
    • ,
  • Lawrence Herz

      Affiliations

    • Veterans Affairs Medical Center, Bedford, and Division of Psychiatry, Boston University School of Medicine, Boston, MA, USA
    • ,
  • Donald R. Miller

      Affiliations

    • Health Services Department, Boston University School of Public Health, Boston, MA, USA
    • Center for Health Quality, Outcomes, and Economic Research, Veterans Affairs Medical Center, Bedford, MA, USA

Received 2 November 2004 ,Revised 31 March 2005 ,Accepted 4 April 2005.

References 

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Anti-psychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156:1686–1696
  2. Andreason N. Symptoms, signs, and diagnosis of schizophrenia. Lancet. 1995;346:477–481
  3. Andreason N, Stephan A, Randall A, Miller D, Flaum M. Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch. Gen. Psychiatry. 1995;52:341–351
  4. Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am. J. Psychiatry. 1997;154:99–105
  5. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 2001;158:518–526
  6. Chiles JA, Miller AL, Crismon ML, Rush AJ, Krasnoff AS, Shon SS. The Texas medication algorithm project: development and implementation of the schizophrenia algorithm. Psychiatr. Serv. 1999;50:69–74
  7. Citrome L, Volavska J. Optimal dosing of atypical anti-psychotics in adults: a review of the current evidence. Harv. Rev. Psychiatr. 2002;10:280–291
  8. Dickey B, Wagenaar H, Stewart A. Using health status measures with the seriously mentally ill in health services research. Med. Care. 1996;34:112–116
  9. Dixon L, Postrado L, Delahanty J, Fisher P, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J. Nerv. Ment. Dis. 1999;187:496–502
  10. Dixon L, Goldberg R, Lehman A, McNary S. The impact of health status on work, symptoms, and functional outcomes in severe mental illness. J. Nerv. Ment. Dis. 2001;189:17–23
  11. Felker B, Yazel JJ, Short D. Mortality and medical comorbidity among psychiatry patients: a review. Psychiatr. Serv. 1996;47:1356–1363
  12. Frackiewicz EJ, Sramek JJ, Herrera K, Kurtz NM, Cutler NR. Ethnicity and antipsychotic response. Ann. Pharmacother. 1997;31:1360–1369
  13. Fuller MA, Shermock KM, Secic M, Laich JS, Durkin MB. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr. Serv. 2002;53:855–860
  14. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:321–330
  15. Haaro, J.M., Edgell, E., Jones, P., Naber, D., Mavreas, V. and Slooff, C., 2003. Change in clinical status and functioning over the first six months of treatment: results from the schizophrenia outpatient health outcomes (SOHO) study. Abstract, presented at the annual meeting of the American Psychiatric Association, San Francisco, CA.
  16. Harding C, Strauss JS, Zubin J. Chronicity in schizophrenia: revisited. Br. J. Psychiatry. 1992;161:27–37
  17. Harvey PD, Lombardi J, Leiman M, White L, Parella M, Powchik P, et al. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr. Res. 1996;22:223–231
  18. Hermann RC, Yang DM, Ettner SL, Marcus SC, Yoon C, Abraham M. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989–1997. Psychiatr. Serv. 2002;53:425–430
  19. Jeste DV, Klausner M, Brecher M, Clyde C, Jones R. A clinical evaluation of risperidone in the treatment of schizophrenia: a 10 week, open-label, multicenter trial (ARCS study group: assessment of risperdal in a clinical setting). Psychopharmacology. 1997;131:239–247
  20. Kane JM. Drug therapy: schizophrenia. N. Engl. J. Med. 1996;334:34–41
  21. Kazis LE, Miller D, Clark J, Katherine S, Lee AF, Rogers W, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch. Intern. Med. 1998;158:626–632
  22. Kazis LE, Ren XS, Lee AF, Katherine S, Rogers W, Clark J, et al. Health status in VA patients: results from the Veterans Health Study using the Veterans SF-36. Am. J. Med. Qual. 1999;14:28–38
  23. Lamoreaux J. The organizational structure for medical information management in the Department of Veterans Affairs: an overview of major health care databases. Med. Care. 1996;34:MS31–MS44
  24. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med. Care. 2001;39:923–933
  25. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr. Res. 1999;35:51–68
  26. Liu GG, Sun SX, Christensen DB, Luo X. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann. Pharmacother. 2004;38:134–141
  27. MacDonald KG. Overview of the epidemiology of obesity and the early history of procedures to remedy morbid obesity. Arch. Surg. 2003;357–360
  28. In:  Murray CJL,  Lopez AD editor. Summary: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press; 1996;
  29. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J. Clin. Psychiatry. 1997;58:45–49
  30. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psychiatry. 1993;50:85–94
  31. Ren XS, Kazis L, Lee AF, Hamed A, Huang YH, Cunningham F, et al. Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. J. Clin. Pharm. Ther. 2003;27:441–451
  32. Ren XS, Lee AF, Huang YH, Hamed A, Herz L, Miller DR, et al. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia. J. Clin. Pharm. Ther. 2004;29:471–481
  33. Ren XS, Huang YH, Lee AF, Miller DR, Qian S, Kazis L. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J. Clin. Pharm. Ther. 2005;30:65–71
  34. Rosenheck R, Douglas L, Michael S. From clinical real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med. Care. 2002;39:302–308
  35. Roy MA, De Vriendt X. Positive and negative symptoms in schizophrenia. A current overview. Can. J. Psychiatry. 1994;39:407–414
  36. Whitehorn D, Rui Q, Kopala LC. Outcomes benchmarks: changes in symptom and function outcome measures from year one to year two endpoints with continuous treatment for a schizophrenia spectrum disorder. Schizophr. Res. 2003;60:348
  37. Zhu B, Gibson PJ, Ascher-Svanum H, Opolka J. A comparison of adherence and persistence levels among schizophrenia patients treated with atypical antipsychotics. Schizophr. Res. 2003;60:349

PII: S0920-9964(05)00139-8

doi: 10.1016/j.schres.2005.04.005

Schizophrenia Research
Volume 77, Issue 2 , Pages 167-177 , 15 September 2005

Article Tools